Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing

It used to be that companies and scientists with ideas for new drugs couldn’t wait to announce their discoveries at meetings, in preprints and on their websites.That is changing.Researchers at the biotechnology firm Alnylam Pharmaceuticals have an unwritten policy: Do not reveal early-stage studies or discuss unpublished data, according to its founding chief executive, Dr.Christoph Westphal.Jacob Becraft of Strand Therapeutics delays filing for patents to keep his company’s discoveries secret.

And he is careful about disclosing his company’s intellectual property and confidential material, even to investors.Alexis Borisy, a co-founder of Curie.Bio, which helps early-stage biotechs, says he tells scientists to “go dark” — don’t publish, don’t present posters at meetings, don’t even go to meetings.The reason for this guarded stance? Fears that Chinese companies will seize on the biotechs’ discoveries and quickly beat them to market with the U.S.firms’ own inventions or with slightly altered versions that dilute market exclusivity.“This is the world we’re in now,” Mr.

Borisy said.Meetings are where scientists discuss new ideas.

Publication is the lifeblood of science.But now, being too open too soon has become too risky, he and others said.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access.

If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe....

Read More 
PaprClips
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by PaprClips.
Publisher: The New York Times

Recent Articles